慢性脑供血不足肾虚血瘀型采用养脑通络汤治疗的临床价值

Clinical value of treating chronic cerebral insufficiency of kidney deficiency and blood stasis type by Yangnao Tongluo Decoction

目的探究养脑通络汤对慢性脑供血不足肾虚血瘀型患者的临床应用价值。方法90例慢性脑供血不足肾虚血瘀型患者,随机分为观察组和对照组,各45例。对照组患者给予盐酸氟桂利嗪胶囊治疗,观察组患者给予养脑通络汤治疗。比较两组患者疗效、血脂指标[甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-L)及高密度脂蛋白胆固醇(HDL-L)]、血栓标志物[纤维蛋白原(FIB)、一氧化氮(NO)及血管内皮素(ET-1)]、药物相关不良反应发生情况、晕厥发作率及生活质量。结果观察组有效率97.78%高于对照组的84.44%,差异有统计学意义(P<0.05)。观察组TG(1.15±0.02)mmol/L、TC(3.42±0.15)mmol/L及LDL-L(1.55±0.02)mmol/L低于对照组的(2.01±0.12)、(5.01±0.56)、(2.65±0.05)mmol/L,HDL-L(1.45±0.02)mmol/L高于对照组的(1.01±0.01)mmol/L,差异有统计学意义(P<0.05)。观察组FIB(2.38±0.12)g/L、ET-1(77.87±8.31)pg/ml低于对照组的(3.25±0.31)g/L、(133.42±11.31)pg/ml,NO(63.25±6.81)μmol/ml高于对照组的(35.34±5.72)μmol/ml,差异有统计学意义(P<0.05)。观察组药物相关不良反应发生率2.22%低于对照组的31.11%,差异有统计学意义(P<0.05)。观察组患者晕厥发作率6.67%低于对照组的33.33%,差异有统计学意义(P<0.05)。观察组躯体评分、社会评分、情感评分、总体健康评分高于对照组,差异有统计学意义(P<0.05)。结论对于慢性脑供血不足肾虚血瘀型患者,养脑通络汤具备更优的疗效及安全性,养脑通络汤可显著改善患者血脂、血栓标志物水平,降低不良反应及晕厥风险,提高患者生活质量,临床应用效果值得肯定,推荐在临床中广泛应用。

Objective To investigate the clinical value of treating chronic cerebral insufficiency of kidney deficiency and blood stasis type by Yangnao Tongluo Decoction.Methods A total of 90 patients with chronic cerebral insufficiency of kidney deficiency and blood stasis type were randomly divided into observation group and control group,with 45 cases in each group.Patients in the control group were treated with flunarizine hydrochloride capsules,and patients in the observation group were treated with Yangnao Tongluo Decoction.Both groups were compared in terms of efficacy,blood lipid indexes[triglycerides(TG),total cholesterol(TC),lowdensity lipoprotein cholesterol(LDL-C)and high-density lipoprotein cholesterol(HDL-C)],thrombosis markers[fibrinogen(FIB),nitric oxide(NO)and vascular endothelin(ET-1)],occurrence of drug-related adverse reactions,incidence of syncope,and quality of life.Results The effective rate 97.78%of the observation group was higher than 84.44%of the control group,and the difference was statistically significant(P<0.05).The TG(1.15±0.02)mmol/L,TC(3.42±0.15)mmol/L and LDL-C(1.55±0.02)mmol/L of the observation group were lower than(2.01±0.12),(5.01±0.56),and(2.65±0.05)mmol/L of the control group,and the HDL-C(1.45±0.02)mmol/L was higher than(1.01±0.01)mmol/L of the control group.All the differences were statistically significant(P<0.05).The FIB(2.38±0.12)g/L and ET-1(77.87±8.31)pg/ml of the observation group were lower than(3.25±0.31)g/L and(133.42±11.31)pg/ml of the control group,and the NO(63.25±6.81)μmol/ml was higher than(35.34±5.72)μmol/ml of the control group.All the differences were statistically significant(P<0.05).The incidence of drug-related adverse reactions 2.22%in the observation group was lower than 31.11%in the control group,and the difference was statistically significant(P<0.05).The incidence of syncope 6.67%in the observation group was lower than 33.33%in the control group,and the difference was statistically significant (P<0.05). The physical score, social score, emotional score, and overall health score of the observation group were higher than those of the control group, and the difference was statistically significant (P<0.05). Conclusion Yangnao Tongluo Decoction has better efficacy and safety for patients with chronic cerebral blood supply deficiency of kidney deficiency and blood stasis type, and it can significantly improve patients’ blood lipid and thrombosis marker levels, reduce the risk of adverse reactions and syncope, and improve patients’ quality of life. It is recommended to be widely used in clinical practice.